NH — AI Stock Dissection

AI Stock Dissection

Fetching the live quote…Computing price structure…Running the AI dissection…Writing the executive briefing…Scoring risks & catalysts…

Sensai

Reading the tape…Pulling live market data…Setting the scene…

AI Stock Dissection

NHLive

Dr. Emmanuel Rupert · Bengaluru, India · 11,234 employees

₹2,070.60

▼-0.11%

NH is riding a revenue momentum wave, with a staggering 75.80% YoY growth, but debt levels pose a concerning challenge.

Exchange

NSI

Currency

INR

Day range

₹2,059.40 – ₹2,092.90

52-week range

₹1,589.00 – ₹2,093.30

Sector

Healthcare

Industry

Medical Care Facilities

AI investment rating

AI analysis

Hold

60% confidence

NH appears moderately overvalued currently, trading in the upper third of its 1-year range and with a high P/E ratio of 52.03.

Position in 52-week range

Live

52w low95%52w high

1.1% below the 1-year high · trend down

Fundamentals

Live

Market cap422.51B

Hedge-fund memo

Executive AI briefing

AI analysis

Today

-0.11% decline on the day, but still within a tight day range (2059.4–2092.9) INR.

This week

Continues its run, but struggling to sustain beyond its 52-week high of 2093.3 INR.

This month

Volume of 152461 is lower than its average, suggesting some caution ahead.

Bull thesis

Revenue growth momentum to sustain beyond FY23.
Improvement in operational efficiency to boost profitability.

Bear thesis

Debt concerns and rising interest rates to weigh on the stock.
Potential regulatory headwinds affecting the healthcare sector.

Hidden risks

News & sentiment

What the press is saying

24 headlines · live

Neutral

24 headlines · 18 outlets · 7d

Tone · daily average

07-2907-30

-20
Officials inspects Phesama sinking zone on NH-2

Smart money

Who owns it

Live

Ownership split

Insiders / promoters67.23%

Institutions (FII/DII/MF)13.05%

Public & others19.719999999999995%

Top institutional holders

Not listed

Named holders aren't published for this listing (common for Indian stocks). The split at left is live.

Financial health

The numbers

Live

Profitability

Return on equity19.84%
Return on assets7.40%
Profit margin10.20%
Operating margin13.72%
Gross margin39.91%

Growth

Revenue (TTM)78.96B
Revenue growth75.80%
Earnings growth13.50%

Balance sheet

Debt / equity129.03%

07b

Financial statements

Multi-year trend

Live

Line item

2023202420252026

Revenue

₹45.2B

₹50.2B

₹56.2B

₹79.0B

Gross profit

₹0

Earnings intelligence

Beat history

Live

Beat estimates in 1 of 4 recent quarters (EPS actual vs. consensus).

2026-03-31Miss

11.2196 vs 13.05

-14.03% surprise

2025-12-31Miss

8.44612 vs 12.55

-32.70% surprise

2025-09-30Beat

12.71 vs 10.8

17.69% surprise

Competitive landscape

Versus peers

Live

Company	Market cap	P/E	ROE	Op. margin	Rev. growth
NHNH	422.51B	52.06	19.84%	13.72%	75.80%
ASTERDMAster DM Quality Care Limited	712.37B	109.41	10.07%	13.98%	18.20%
LALPATHLABDr. Lal PathLabs Limited	313.72B	58.02	—

Technical intelligence

Price structure

Live

NHdaily · candles

Hover the chart for that day's open / high / low / close, volume and RSI.

Volume

RSI (14) · 70 overbought / 30 oversold

MACD (12,26,9) · MACD vs signal

Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.

Risk intelligence

What could go wrong

AI analysis

Debt burden and interest rate risk

P: HighImpact: Medium

Mitigation: NH should focus on debt repayment and reducing its debt-to-equity ratio.

Regulatory challenges

P: MediumImpact: Low

Mitigation: NH should engage with regulatory bodies to address any concerns and comply with changing regulations.

Business intelligence

Moat · supply chain · M&A

AI analysis

Competitive moat

NH's focus on multi-specialty hospitals with high-quality medical services provides a sustainable competitive edge in the Indian healthcare sector.

Supply chain

Upstream (inputs / suppliers)

High-quality medical devices and equipmentSkilled medical professionals

↓

Downstream (customers / markets)

Growing demand for quality healthcare services across India

M&A / strategic moves

NH has made strategic investments in digital healthcare platforms to enhance its offerings and improve patient engagement.

Catalyst calendar

What to watch next

AI analysis

Q2 FY24 earningsMedium impact
Revenue growth guidance for FY24

Thesis builder

Bull / base / bear

AI analysis

Bull case

NH can sustain its growth momentum and reach INR 3000 by FY28, driven by a CAGR of 20-25%.

Base case

NH is poised to maintain its market share in the Indian healthcare sector, with a stable CAGR of 10-15%. Entry at INR 2000, exit at INR 2400.

Bear case

NH faces significant debt burden and regulatory challenges, resulting in a CAGR of -5-10% in the medium term.

Time horizon

Short-term (6-12 months): focus on managing debt and sustaining revenue growth. Medium-term (1-3 years): watch for signs of operational improvement and growth sustainability.

Est. CAGR

20-25%

Entry (qual.)

Look for dips to levels near INR 1800-1900, where the stock has shown buying interest in the past.

Exit (qual.)

Consider booking profits when the stock breaks above INR 2400-2500, reflecting sustained growth and improved fundamentals.

Knowledge graph

How it all connects

Entity graph

Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.

Portfolio impact

Does it fit your book?

Your holdings

Enter tickers + weights, then see how NH fits.

Enter your portfolio and hit “Analyze fit” to see NH's correlation, diversification benefit, and concentration impact.

Scenario simulator

Stress the thesis

Simulate a macro shock and see the illustrative impact:

Tailwind for tech & enablers.

Illustrative impact

Medium prob.

Revenue+6%

EPS+9%

Valuation+14%

Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.

Explain like…

Tailored explanations

Re-explain NH for a different audience:

Pick a persona to get a tailored explanation.

Important disclaimer

Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.

Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.

Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.

Position in 52-week range

Fundamentals

Executive AI briefing

What the press is saying

Who owns it

Ownership split

Top institutional holders

The numbers

Multi-year trend

Beat history

Versus peers

Price structure

What could go wrong

Moat · supply chain · M&A

What to watch next

Bull / base / bear

How it all connects

Entity graph

Does it fit your book?

Your holdings

Stress the thesis

Tailored explanations

Important disclaimer

Levels & position

Oscillators & averages